MOLOGEN AG
MOLOGEN to present poster at European Cancer Congress 2015 (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Conference PRESS RELEASE N 16 / 2015 of 09/24/2015 MOLOGEN to present poster at European Cancer Congress 2015 Berlin, September 24, 2015 – The biotechnology company MOLOGEN AG will present a poster on the immunotherapy MGN1703 at the European Cancer Congress (ECC 2015) in Vienna (September 25 – 29, 2015). The poster is featuring data from the phase II IMPACT trial in colorectal cancer patients. Furthermore, in the framework of the conference, an investigator meeting is scheduled for the randomized lung cancer study IMPULSE. Abstract details: For more information on the ECC 2015 please visit the website www.europeancancercongress.org . MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200). Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=IWIFPCXMRE Document title: MOLOGEN to present poster at European Cancer Congress 2015 2015-09-24 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |
397117 2015-09-24 |